These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DELAWARE
|
|
95-4405754
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
o
|
|
|
|
|
Emerging growth company
o
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
|
|
||
|
ACACIA RESEARCH CORPORATION
|
|||
|
Table Of Contents
|
|||
|
|
|
|
|
|
Part I.
|
Financial Information
|
|
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
|
|
|
|
|
|
Part II.
|
Other Information
|
||
|
|
|
|
|
|
|
Item 1A.
|
Risk Factors
|
|
|
|
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
|
|
|
|
|
|
Signatures
|
|
||
|
|
|
|
|
|
Exhibit Index
|
|
||
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
ASSETS
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
150,289
|
|
|
$
|
136,604
|
|
|
Short-term investments
|
29,359
|
|
|
—
|
|
||
|
Accounts receivable
|
4,754
|
|
|
153
|
|
||
|
Prepaid expenses and other current assets
|
3,801
|
|
|
2,938
|
|
||
|
Total current assets
|
188,203
|
|
|
139,695
|
|
||
|
|
|
|
|
||||
|
Investment at fair value
(1)
|
63,657
|
|
|
104,754
|
|
||
|
Other investments
(1)
|
8,195
|
|
|
2,195
|
|
||
|
Patents, net of accumulated amortization
|
56,587
|
|
|
61,917
|
|
||
|
Other assets
|
1,193
|
|
|
207
|
|
||
|
|
$
|
317,835
|
|
|
$
|
308,768
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable and accrued expenses
|
$
|
9,040
|
|
|
$
|
7,956
|
|
|
Royalties and contingent legal fees payable
|
39,937
|
|
|
1,601
|
|
||
|
Total current liabilities
|
48,977
|
|
|
9,557
|
|
||
|
Other liabilities
|
1,805
|
|
|
3,552
|
|
||
|
Total liabilities
|
50,782
|
|
|
13,109
|
|
||
|
Commitments and contingencies (Note 6)
|
|
|
|
|
|
||
|
Stockholders’ equity:
|
|
|
|
|
|
||
|
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding
|
—
|
|
|
—
|
|
||
|
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 50,647,882 and 50,639,926 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively
|
51
|
|
|
51
|
|
||
|
Treasury stock, at cost, 1,729,408 shares as of March 31, 2018 and December 31, 2017
|
(34,640
|
)
|
|
(34,640
|
)
|
||
|
Additional paid-in capital
|
649,724
|
|
|
648,996
|
|
||
|
Accumulated comprehensive loss
|
(125
|
)
|
|
(88
|
)
|
||
|
Accumulated deficit
|
(349,550
|
)
|
|
(320,018
|
)
|
||
|
Total Acacia Research Corporation stockholders’ equity
|
265,460
|
|
|
294,301
|
|
||
|
Noncontrolling interests
|
1,593
|
|
|
1,358
|
|
||
|
Total stockholders’ equity
|
267,053
|
|
|
295,659
|
|
||
|
|
$
|
317,835
|
|
|
$
|
308,768
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Revenues
|
$
|
62,093
|
|
|
$
|
8,854
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
||
|
Cost of revenues:
|
|
|
|
|
|
||
|
Inventor royalties
|
21,744
|
|
|
666
|
|
||
|
Contingent legal fees
|
15,759
|
|
|
627
|
|
||
|
Other
|
4,000
|
|
|
—
|
|
||
|
Litigation and licensing expenses - patents
|
2,745
|
|
|
6,386
|
|
||
|
Amortization of patents
|
5,330
|
|
|
5,515
|
|
||
|
General and administrative expenses
(2)
|
3,379
|
|
|
6,916
|
|
||
|
Other expenses - business development
|
166
|
|
|
320
|
|
||
|
Total operating costs and expenses
|
53,123
|
|
|
20,430
|
|
||
|
Operating income (loss)
|
8,970
|
|
|
(11,576
|
)
|
||
|
|
|
|
|
|
|
||
|
Other income (expense):
|
|
|
|
||||
|
Change in fair value of investment, net
(1)
|
(41,097
|
)
|
|
—
|
|
||
|
Interest income and other
|
207
|
|
|
696
|
|
||
|
Total other income (expense)
|
(40,890
|
)
|
|
696
|
|
||
|
Loss before provision for income taxes
|
(31,920
|
)
|
|
(10,880
|
)
|
||
|
Provision for income taxes
|
(191
|
)
|
|
(1,241
|
)
|
||
|
Net loss including noncontrolling interests in subsidiaries
|
(32,111
|
)
|
|
(12,121
|
)
|
||
|
Net loss attributable to noncontrolling interests in subsidiaries
|
73
|
|
|
291
|
|
||
|
Net loss attributable to Acacia Research Corporation
|
$
|
(32,038
|
)
|
|
$
|
(11,830
|
)
|
|
|
|
|
|
|
|
||
|
Net loss attributable to common stockholders - basic and diluted
|
$
|
(32,038
|
)
|
|
$
|
(11,830
|
)
|
|
Basic and diluted net loss per common share
|
$
|
(0.63
|
)
|
|
$
|
(0.24
|
)
|
|
Weighted average number of shares outstanding - basic and diluted
|
50,632,958
|
|
|
50,333,056
|
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
General and administrative expenses
|
$
|
4,403
|
|
|
$
|
4,788
|
|
|
Non-cash stock compensation expense - G&A
|
704
|
|
|
2,112
|
|
||
|
Non-cash stock compensation expense - Profits Interests (Note 7)
|
(1,728
|
)
|
|
16
|
|
||
|
Total general and administrative expenses
|
$
|
3,379
|
|
|
$
|
6,916
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Net loss including noncontrolling interests
|
$
|
(32,111
|
)
|
|
$
|
(12,121
|
)
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
||
|
Unrealized gain (loss) on short-term investments, net of tax of $0
|
(20
|
)
|
|
14
|
|
||
|
Unrealized gain (loss) on foreign currency translation, net of tax of $0
|
(17
|
)
|
|
13
|
|
||
|
Total other comprehensive loss
|
(32,148
|
)
|
|
(12,094
|
)
|
||
|
Comprehensive loss attributable to noncontrolling interests
|
73
|
|
|
291
|
|
||
|
Comprehensive loss attributable to Acacia Research Corporation
|
$
|
(32,075
|
)
|
|
$
|
(11,803
|
)
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net loss including noncontrolling interests in subsidiaries
|
$
|
(32,111
|
)
|
|
$
|
(12,121
|
)
|
|
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:
|
|
|
|
|
|
||
|
Change in fair value of investment, net
(1)
|
41,097
|
|
|
—
|
|
||
|
Depreciation and amortization
|
5,344
|
|
|
5,540
|
|
||
|
Non-cash stock compensation
|
(1,024
|
)
|
|
2,128
|
|
||
|
Other
|
(87
|
)
|
|
(348
|
)
|
||
|
Changes in assets and liabilities:
|
|
|
|
|
|||
|
Accounts receivable
|
(59
|
)
|
|
18,969
|
|
||
|
Prepaid expenses and other assets
|
(863
|
)
|
|
(1,738
|
)
|
||
|
Accounts payable and accrued expenses
|
1,065
|
|
|
(2,576
|
)
|
||
|
Royalties and contingent legal fees payable
|
36,608
|
|
|
(10,830
|
)
|
||
|
Net cash provided by (used in) operating activities
|
49,970
|
|
|
(976
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Investments in Investees
(1)
|
(7,000
|
)
|
|
—
|
|
||
|
Advances to Investee
(1)
|
—
|
|
|
(1,000
|
)
|
||
|
Purchases of available-for-sale investments
|
(33,309
|
)
|
|
(174,152
|
)
|
||
|
Maturities and sales of available-for-sale investments
|
4,000
|
|
|
102,682
|
|
||
|
Net cash used in investing activities
|
(36,309
|
)
|
|
(72,470
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Repurchased restricted common stock
|
(7
|
)
|
|
(25
|
)
|
||
|
Proceeds from exercises of stock options
|
31
|
|
|
255
|
|
||
|
Net cash provided by financing activities
|
24
|
|
|
230
|
|
||
|
|
|
|
|
|
|
||
|
Increase (decrease) in cash and cash equivalents
|
13,685
|
|
|
(73,216
|
)
|
||
|
Cash and cash equivalents and restricted cash (2017 period only), beginning
|
136,604
|
|
|
139,052
|
|
||
|
Cash and cash equivalents and restricted cash (2017 period only), ending
|
$
|
150,289
|
|
|
$
|
65,836
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Paid-up Revenue Agreements
|
$
|
60,063
|
|
|
$
|
7,196
|
|
|
Recurring Revenue Agreements
|
2,030
|
|
|
1,658
|
|
||
|
|
$
|
62,093
|
|
|
$
|
8,854
|
|
|
(i)
|
Level 1
-
Observable Inputs
: Quoted prices in active markets for identical investments;
|
|
(ii)
|
Level 2
-
Pricing Models with Significant Observable Inputs
: Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and
|
|
(iii)
|
Level 3
-
Unobservable Inputs
: Significant unobservable inputs, including the entity’s own assumptions in determining the fair value of investments.
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||
|
Assets as of March 31, 2018:
|
|
|
|
|
|
||||||
|
Short-term investments
(1)
|
$
|
29,359
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Investment at fair value (Note 5)
(1)
|
—
|
|
|
—
|
|
|
63,657
|
|
|||
|
Total recurring fair value measurements
|
$
|
29,359
|
|
|
$
|
—
|
|
|
$
|
63,657
|
|
|
Assets as of December 31, 2017:
|
|
|
|
|
|
||||||
|
Investment at fair value (Note 5)
(1)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104,754
|
|
|
|
Investment at Fair Value
|
||||||||||
|
|
Common Stock
|
|
Warrants
|
|
Total
|
||||||
|
Opening balance as of January 1, 2018
|
$
|
90,795
|
|
|
$
|
13,959
|
|
|
$
|
104,754
|
|
|
Total gains and losses included in earnings for the period
(1)
|
|
|
|
|
|
||||||
|
Change in fair value of investment, net
|
(33,450
|
)
|
|
(7,647
|
)
|
|
(41,097
|
)
|
|||
|
Total recurring fair value measurements
(1)
|
$
|
57,345
|
|
|
$
|
6,312
|
|
|
$
|
63,657
|
|
|
|
|
|
Gross Unrealized
|
|
|
||||||||||
|
Security Type
|
Cost
|
|
Gains
|
|
Losses
|
|
Fair Value
|
||||||||
|
March 31, 2018:
|
|
|
|
|
|
|
|
||||||||
|
U.S. government fixed income securities (Maturity dates in 2018)
|
$
|
29,378
|
|
|
$
|
—
|
|
|
$
|
(19
|
)
|
|
$
|
29,359
|
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
|
2018
|
|
2017
|
||||
|
Weighted-average shares used in computing net loss per share attributable to common stockholders – basic and diluted
|
|
50,632,958
|
|
|
50,333,056
|
|
||
|
Basic and diluted net loss per common share
|
|
$
|
(0.63
|
)
|
|
$
|
(0.24
|
)
|
|
Anti-dilutive equity-based incentive awards excluded from the computation of diluted loss per share
|
|
5,898,369
|
|
|
4,420,717
|
|
||
|
Maximum price of awards excluded from the computation of diluted loss per share
|
|
$
|
6.75
|
|
|
$
|
6.75
|
|
|
For the years ending December 31,
|
|
||
|
Remainder of 2018
|
$
|
15,212
|
|
|
2019
|
18,527
|
|
|
|
2020
|
6,134
|
|
|
|
2021
|
5,261
|
|
|
|
2022
|
5,256
|
|
|
|
Thereafter
|
6,197
|
|
|
|
|
$
|
56,587
|
|
|
|
|
Veritone Common Stock
|
|
Veritone Warrants
|
|
|
|||||||||||
|
|
|
IPO Date
|
|
December 31,
2017 |
|
March 31,
2018 |
|
IPO Date
|
|
December 31,
2017 |
|
March 31,
2018 |
|||||
|
Estimated DLOM applied
|
|
5.7%
|
|
5%
|
|
—
|
|
5.7%
|
|
10%
|
|
5%
|
-
|
15%
|
|||
|
Volatility assumptions
|
|
35%
|
|
37%
|
|
—
|
|
35%
|
|
72
|
%
|
-
|
87%
|
|
51%
|
-
|
91%
|
|
Term assumptions
|
|
6 months
|
|
2 months
|
|
—
|
|
6 months
|
|
5 months
|
|
5 months
|
|||||
|
|
|
Year Ended
December 31, 2017 |
||
|
Revenues
|
|
$
|
14,413
|
|
|
Gross profit
|
|
1,070
|
|
|
|
Operating expenses
|
|
60,105
|
|
|
|
Other income (expense), net
|
|
(12,833
|
)
|
|
|
Net loss attributable to common stockholders
|
|
(64,071
|
)
|
|
|
|
|
|
||
|
Net loss per share attributable to common stockholders - basic and diluted
|
|
$
|
(6.20
|
)
|
|
|
|
December 31, 2017
|
||
|
Current assets
|
|
$
|
83,805
|
|
|
Noncurrent assets
|
|
4,753
|
|
|
|
Total Assets
|
|
$
|
88,558
|
|
|
|
|
|
||
|
Current liabilities
|
|
$
|
27,256
|
|
|
Noncurrent liabilities
|
|
—
|
|
|
|
Total liabilities
|
|
27,256
|
|
|
|
Preferred stock
|
|
—
|
|
|
|
Total stockholder's equity (deficit)
|
|
61,302
|
|
|
|
Total liabilities, preferred stock and stockholders’ equity
|
|
$
|
88,558
|
|
|
|
|
Balance at December 31, 2017
|
|
Adjustments Due to ASC 606
|
|
Balance at January 1, 2018
|
||||||
|
Balance Sheets:
|
|
|
|
|
|
|
||||||
|
Accounts receivable
|
|
$
|
153
|
|
|
$
|
4,542
|
|
|
$
|
4,695
|
|
|
Royalties and contingent legal fees payable
|
|
1,601
|
|
|
1,728
|
|
|
3,329
|
|
|||
|
Accumulated deficit
|
|
(320,018
|
)
|
|
2,506
|
|
|
(317,512
|
)
|
|||
|
Noncontrolling interests
|
|
1,358
|
|
|
308
|
|
|
1,666
|
|
|||
|
|
|
Balance as Reported
|
|
Balance Before ASC 606 Adoption
|
|
Effect of Change
|
||||||
|
Balance Sheets:
|
|
|
|
|
|
|
||||||
|
Accounts receivable
|
|
$
|
4,754
|
|
|
$
|
2,724
|
|
|
$
|
2,030
|
|
|
Royalties and contingent legal fees payable
|
|
39,937
|
|
|
39,125
|
|
|
812
|
|
|||
|
|
|
|
|
|
|
|
||||||
|
Statements of Operations:
|
|
|
|
|
|
|
||||||
|
Revenues
|
|
$
|
62,093
|
|
|
$
|
60,063
|
|
|
$
|
2,030
|
|
|
Inventor royalties
|
|
21,744
|
|
|
21,046
|
|
|
698
|
|
|||
|
Contingent legal fees
|
|
15,759
|
|
|
15,645
|
|
|
114
|
|
|||
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Revenues (in thousands)
|
$
|
62,093
|
|
|
$
|
8,854
|
|
|
New agreements executed
|
4
|
|
|
6
|
|
||
|
Licensing and enforcement programs generating revenues
|
4
|
|
|
8
|
|
||
|
•
|
the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee;
|
|
•
|
the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments;
|
|
•
|
fluctuations in the total number of agreements executed each period;
|
|
•
|
the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs;
|
|
•
|
the relative maturity of licensing programs during the applicable periods;
|
|
•
|
other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors;
|
|
•
|
historically, based on the merits and strength of our operating subsidiary’s patent infringement claims and other factors, many prospective licensees have elected to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as those patent infringement cases approached a court determined trial date; and
|
|
•
|
fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above.
|
|
•
|
Bone Wedge technology
(1)(2)
|
|
•
|
Electronic Access Control technology
(2)
|
|
•
|
Speech codes used in wireless and wireline systems technology
(1)(2)
|
|
•
|
Innovative Display technology
(2)
|
|
•
|
Super Resolutions Microscopy technology
(1)(2)
|
|
•
|
Online Auction Guarantee technology
(2)
|
|
•
|
Video Conferencing technology
(1)
|
|
•
|
Optical Networking technology
(2)
|
|
•
|
DisplayPort and MIPI DSI technology
(2)
|
|
|
|
|
|
Three Months Ended
March 31, |
|
%
|
|||||||
|
|
2018
|
|
2017
|
|
Change
|
|||||
|
|
|
|
|
|
|
|||||
|
Revenues
|
$
|
62,093
|
|
|
$
|
8,854
|
|
|
*
|
|
|
Operating costs and expenses
|
53,123
|
|
|
20,430
|
|
|
160
|
%
|
||
|
Operating income (loss)
|
8,970
|
|
|
(11,576
|
)
|
|
(177
|
)%
|
||
|
Other income (expense), net
|
(40,890
|
)
|
|
696
|
|
|
*
|
|
||
|
Loss before provision for income taxes
|
(31,920
|
)
|
|
(10,880
|
)
|
|
193
|
%
|
||
|
Provision for income taxes
|
(191
|
)
|
|
(1,241
|
)
|
|
85
|
%
|
||
|
Net loss attributable to Acacia Research Corporation
|
(32,038
|
)
|
|
(11,830
|
)
|
|
(171
|
)%
|
||
|
•
|
Revenues increased
$53.2 million
to
$62.1 million
for the three months ended
March 31, 2018
, as compared to
$8.9 million
in the comparable prior year quarter,
due primarily to an increase in
the average revenue per agreement executed during the quarter. Refer to “
Investments in Patent Portfolios”
below for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
|
|
•
|
Loss before provision for income taxes was
$31.9 million
for the three months ended
March 31, 2018
, as compared to
$10.9 million
for the three months ended
March 31, 2017
. The net change was primarily comprised of the change in revenues described above, a
$41.1 million
unrealized loss on our equity investment in Veritone and other changes in operating expenses as follows:
|
|
•
|
Inventor royalties, contingent legal fees and other costs of revenue, on a combined basis, increased
$40.2 million
, primarily due to the increase in related revenues for the periods.
|
|
•
|
Litigation and licensing expenses-patents decreased
$3.6 million
, or
57%
, to
$2.7 million
,
due primarily to a net decrease in litigation support and third-party technical consulting expenses associated with ongoing licensing and enforcement programs and an overall decrease in portfolio related enforcement activities.
Refer to “
Investments in Patent Portfolios”
below for additional information regarding the impact of portfolio acquisition trends on licensing and enforcement activities and current and future licensing and enforcement related revenues.
|
|
•
|
General and administrative expenses, excluding non-cash stock compensation, decreased
$385,000
or
8%
, to
$4.4 million
,
due primarily to a reduction in personnel costs in connection with headcount reductions in 2017, a decrease in severance costs and a decrease in corporate, general and administrative costs.
|
|
•
|
Net non-cash stock compensation expense decreased
$3.2 million
, or
148%
, due to the decrease in the fair value of our Veritone related profits interest units, or Profits Interests, consistent with the decrease in the underlying Veritone stock price since December 31, 2017. In addition, first quarter 2017 non-cash stock compensation expense included amounts related to the August 2016 grant of options with market-based vesting conditions with graded vesting features, resulting in higher non-cash stock compensation expense during the earlier stages of the applicable service period. Excluding non-cash stock compensation related to the Profits Interest, non-cash stock compensation expense decreased
$1.4 million
, or
67%
.
|
|
•
|
Results for the three months ended
March 31, 2018
included an unrealized loss on our investment in Veritone totaling
$41.1 million
, related to the application of the fair value method of accounting to our investment in Veritone as of
March 31, 2018
.
|
|
•
|
Increases in patent-related legal expenses associated with patent infringement litigation, including, but not limited to, increases in costs billed by outside legal counsel for discovery, depositions, economic analyses, damages assessments, expert witnesses and other consultants, re-exam and i
nter partes review costs,
case-related audio/video presentations and other litigation support and administrative costs could increase our operating costs and decrease our profit generating opportunities;
|
|
•
|
Our patented technologies and enforcement actions are complex and, as a result, we may be required to appeal adverse decisions by trial courts in order to successfully enforce our patents. Moreover, such appeals may not be successful;
|
|
•
|
New legislation, regulations or rules related to enforcement actions, including any fee or cost shifting provisions, could significantly increase our operating costs and decrease our profit generating opportunities.
Increased focus on the growing number of patent-related lawsuits may result in legislative changes which increase our costs and related risks of asserting patent enforcement actions. For instance, the United States House of Representatives passed a bill that would require non-practicing entities that bring patent infringement lawsuits to pay legal costs of the defendants, if the lawsuits are unsuccessful and certain standards are not met;
|
|
•
|
Courts may rule that our subsidiaries have violated certain statutory, regulatory, federal, local or governing rules or standards by pursuing such enforcement actions, which may expose us and our operating subsidiaries to material liabilities, which could harm our operating results and our financial position; and
|
|
•
|
The complexity of negotiations and potential magnitude of exposure for potential infringers associated with higher quality patent portfolios may lead to increased intervals of time between the filing of litigation and potential revenue events (i.e. markman dates, trial dates), which may lead to increased legal expenses, consistent with the higher revenue potential of such portfolios.
|
|
|
|
Balance at December 31, 2017
|
|
Adjustments Due to ASC 606
|
|
Balance at January 1, 2018
|
||||||
|
Balance Sheets:
|
|
|
|
|
|
|
||||||
|
Accounts receivable
|
|
$
|
153
|
|
|
$
|
4,542
|
|
|
$
|
4,695
|
|
|
Royalties and contingent legal fees payable
|
|
1,601
|
|
|
1,728
|
|
|
3,329
|
|
|||
|
Accumulated deficit
|
|
(320,018
|
)
|
|
2,506
|
|
|
(317,512
|
)
|
|||
|
Noncontrolling interests
|
|
1,358
|
|
|
308
|
|
|
1,666
|
|
|||
|
|
|
Balance as Reported
|
|
Balance Before ASC 606 Adoption
|
|
Effect of Change
|
||||||
|
Balance Sheets:
|
|
|
|
|
|
|
||||||
|
Accounts receivable
|
|
$
|
4,754
|
|
|
$
|
2,724
|
|
|
$
|
2,030
|
|
|
Royalties and contingent legal fees payable
|
|
39,937
|
|
|
39,125
|
|
|
812
|
|
|||
|
|
|
|
|
|
|
|
||||||
|
Statements of Operations:
|
|
|
|
|
|
|
||||||
|
Revenues
|
|
$
|
62,093
|
|
|
$
|
60,063
|
|
|
$
|
2,030
|
|
|
Inventor royalties
|
|
21,744
|
|
|
21,046
|
|
|
698
|
|
|||
|
Contingent legal fees
|
|
15,759
|
|
|
15,645
|
|
|
114
|
|
|||
|
|
|
Three Months Ended
March 31, |
|
Change
|
||||||||||
|
|
|
2018
|
|
2017
|
|
$
|
|
%
|
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenues (in thousands, except percentage change values)
|
|
$
|
62,093
|
|
|
$
|
8,854
|
|
|
$
|
53,239
|
|
|
*
|
|
New agreements executed
|
|
4
|
|
|
6
|
|
|
|
|
|
||||
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2018
|
|
2017
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
Loss before provision for income taxes
|
|
$
|
(31,920
|
)
|
|
$
|
(10,880
|
)
|
|
$
|
(21,040
|
)
|
|
193
|
%
|
|
|
Three Months Ended
March 31, |
|
|
|||
|
|
2018 vs. 2017
|
|
%
|
|||
|
|
(in thousands, except percentage values)
|
|||||
|
Increase in revenues
|
$
|
53,239
|
|
|
(253
|
)%
|
|
Increase in inventor royalties, contingent legal fees and other
|
(40,210
|
)
|
|
191
|
%
|
|
|
Decrease in general and administrative expenses
|
385
|
|
|
(2
|
)%
|
|
|
Decrease in non-cash stock compensation expenses
|
3,152
|
|
|
(15
|
)%
|
|
|
Decrease in litigation and licensing expenses
|
3,641
|
|
|
(17
|
)%
|
|
|
Decrease in patent amortization expenses
|
185
|
|
|
(1
|
)%
|
|
|
Loss on fair value investment
|
(41,097
|
)
|
|
195
|
%
|
|
|
Other
|
(335
|
)
|
|
2
|
%
|
|
|
Total change in loss before provision for income taxes
|
$
|
(21,040
|
)
|
|
100
|
%
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2018
|
|
2017
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
Inventor royalties
|
|
$
|
21,744
|
|
|
$
|
666
|
|
|
$
|
21,078
|
|
|
*
|
|
|
Contingent legal fees
|
|
$
|
15,759
|
|
|
$
|
627
|
|
|
$
|
15,132
|
|
|
*
|
|
|
Other
|
|
$
|
4,000
|
|
|
$
|
—
|
|
|
$
|
4,000
|
|
|
100
|
%
|
|
|
|
Three Months Ended March 31,
|
|
%
|
|||
|
|
|
2018 vs. 2017
|
|
||||
|
Inventor Royalties:
|
|
|
|||||
|
Increase in total revenues
|
|
$
|
18,758
|
|
|
89
|
%
|
|
Increase in inventor royalty rates
|
|
2,320
|
|
|
11
|
%
|
|
|
Total change in inventor royalties expense
|
|
$
|
21,078
|
|
|
100
|
%
|
|
|
|
Three Months Ended March 31,
|
|
%
|
|||
|
|
|
2018 vs. 2017
|
|
||||
|
Contingent Legal Fees:
|
|
|
|
|
|||
|
Increase in total revenues
|
|
$
|
13,595
|
|
|
90
|
%
|
|
Increase in contingent legal fee rates
|
|
1,537
|
|
|
10
|
%
|
|
|
Total change in contingent legal fees expense
|
|
$
|
15,132
|
|
|
100
|
%
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2018
|
|
2017
|
|
$
|
|
%
|
|||||||
|
|
|
(in thousands, except percentage change values)
|
|||||||||||||
|
Litigation and licensing expenses - patents
|
|
$
|
2,745
|
|
|
$
|
6,386
|
|
|
$
|
(3,641
|
)
|
|
(57
|
)%
|
|
Amortization of patents
|
|
$
|
5,330
|
|
|
$
|
5,515
|
|
|
$
|
(185
|
)
|
|
(3
|
)%
|
|
|
|
Three Months Ended
March 31, |
|
Change
|
|||||||||||
|
|
|
2018
|
|
2017
|
|
$
|
|
%
|
|||||||
|
|
|
|
|
|
|
|
|||||||||
|
General and administrative expenses
|
|
$
|
4,403
|
|
|
$
|
4,788
|
|
|
$
|
(385
|
)
|
|
(8
|
)%
|
|
Non-cash stock compensation expense - G&A
|
|
704
|
|
|
2,112
|
|
|
(1,408
|
)
|
|
(67
|
)%
|
|||
|
Non-cash stock compensation expense - Profits Interests
|
|
$
|
(1,728
|
)
|
|
$
|
16
|
|
|
$
|
(1,744
|
)
|
|
*
|
|
|
Total general and administrative expenses
|
|
$
|
3,379
|
|
|
$
|
6,916
|
|
|
$
|
(3,537
|
)
|
|
(51
|
)%
|
|
|
Three Months Ended
March 31, |
|
|
|||
|
|
2018 vs. 2017
|
|
%
|
|||
|
|
|
|||||
|
Personnel cost reductions due to headcount reductions
|
$
|
(584
|
)
|
|
17
|
%
|
|
Variable performance-based compensation costs
|
711
|
|
|
(20
|
)%
|
|
|
Corporate, general and administrative costs
|
(175
|
)
|
|
5
|
%
|
|
|
Non-cash stock compensation expense
|
(3,152
|
)
|
|
89
|
%
|
|
|
Non-recurring employee severance costs
|
(337
|
)
|
|
9
|
%
|
|
|
Total change in general and administrative expenses
|
$
|
(3,537
|
)
|
|
100
|
%
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Provision for income taxes (in thousands)
|
$
|
(191
|
)
|
|
$
|
(1,241
|
)
|
|
Effective tax rate
|
(1
|
)%
|
|
(11
|
)%
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Net cash provided by (used in):
|
|
|
|
||||
|
Operating activities
|
$
|
49,970
|
|
|
$
|
(976
|
)
|
|
Investing activities
|
(36,309
|
)
|
|
(72,470
|
)
|
||
|
Financing activities
|
24
|
|
|
230
|
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
|
|
|
|
||||
|
Investments in Investees
|
$
|
(7,000
|
)
|
|
$
|
—
|
|
|
Advances to Investee
|
—
|
|
|
(1,000
|
)
|
||
|
Available-for-sale investments, net (cash management activities)
|
(29,309
|
)
|
|
(71,470
|
)
|
||
|
Net cash used in investing activities
|
$
|
(36,309
|
)
|
|
$
|
(72,470
|
)
|
|
|
Payments Due by Period (In thousands)
|
||||||||||||||
|
Contractual Obligations
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
3-5 years
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
Operating leases, net of guaranteed sublease income
|
$
|
2,266
|
|
|
$
|
882
|
|
|
$
|
1,384
|
|
|
$
|
—
|
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
31.1#
|
|
|
31.2#
|
|
|
32.1**#
|
|
|
32.2**#
|
|
|
101#
|
|
|
#
|
Filed herewith.
|
|
**
|
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
|
|
|
ACACIA RESEARCH CORPORATION
|
|
|
|
|
|
/
s/ Robert Stewart
|
|
|
By:
Robert Stewart
|
|
|
President
|
|
|
(Principal Executive Officer and Duly Authorized Signatory)
|
|
|
|
|
|
/s/ Clayton J. Haynes
|
|
|
By: Clayton J. Haynes
|
|
|
Chief Financial Officer and Treasurer
|
|
|
(Principal Financial and Accounting Officer)
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
31.1#
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
31.2#
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
32.1**#
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
32.2**#
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
101#
|
Interactive Data Files Pursuant to Rule 405 of Regulation S-T.
|
|
#
|
Filed herewith.
|
|
**
|
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|